entertainment -WSS

entertainment

author：focus 2025-09-30 23:11:09 - browse：285

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Ozempic has benefits for kidney disease as well as diabetes

leisure time

focus

WSS

Lack of health data on LGBTQ+ people has serious consequences

Scrutiny of post

Families look for replacement for GSK asthma drug Flovent

Fetal cell organoids grown from amniotic fluid, study finds

Cue Health, Covid

Lack of health data on LGBTQ+ people has serious consequences

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medicare details structure of new drug price negotiation program

Listen: More tumult at BIO & coercive care for sickle cell patients

Guidelines to prevent youth baseball injuries need more muscle

For AI in health care standards, federal regulators join with industry group

Heart attack and stroke risk calculators need revising

Change Healthcare: What is it, why does its cyberattack matter?

Anesthesiologist group: stop taking Ozempic before surgery

As a primary care physician, here's how I hope to partner with AI

In Memoriam: Notable people who died in 2023

Biden's 'march

entertainment

$1 billion proposal to grow Boston, Massachusetts biotech

Reports of telehealth's death have been greatly exaggerated

Longer MASH drug regimen improved liver, Akero study finds

Study finds gene variants tied to breast cancer risk in Black women

Families look for replacement for GSK asthma drug Flovent

Harvard's David Sinclair gets blowback over aging

leisure time

leisure time

focus

explore